Advances In HF: A Year In Discovery – SGLT2i Trials And Implications For Clinical Practice

Published: 20 January 2021

  • Views:

    Views Icon 5529
  • Likes:

    Heart Icon 3

Overview

Full programme

  • Views:

    Views Icon 5529
  • Likes:

    Heart Icon 3

Overview

In this special end of year round-up, we hear two leading lights in heart failure (HF), Dr Shelley Zieroth and Dr Ileana Pina, discussing the totality of evidence from recent SGLT-2 inhibitor trials in HF. Their insightful discussion has been sectioned into three distinct chapters:

  • Chapter 1: Trial populations and major endpoints
  • Chapter 2: Quality of life and safety
  • Chapter 3: Future SGLT2 trials and sequencing of HF medications

Videographer: Mike Knight

Recorded remotely from Winnipeg and New York.

Series overview

Part 1

Chapter 1: Trial populations and major endpoints

Chapter 1: Trial populations and major endpoints

1 session

  • Chapter 1: Trial populations and major endpoints

    Watch now

Part 2

Chapter 2: Quality of life and safety

Chapter 2: Quality of life and safety

1 session

  • Chapter 2: Quality of life and safety

    Watch now

Part 3

Chapter 3: Future SGLT2 trials and sequencing of HF medications

Chapter 3: Future SGLT2 trials and sequencing of HF medications

1 session

  • Chapter 3: Future SGLT-2 trials and sequencing of HF medications

    Watch now

Faculty biographies